GlassScriptPhysician profile
Jessica E Mclaughlin
NPI 1861755712
$3,280.32
in general payments reported to CMS, 2019-2025
8 companies · $769 in 2025
The $769 reported for 2025 was more than what 91% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $256 · 2021: $313 · 2022: $589 · 2023: $440 · 2024: $481 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,550 · Food and Beverage: $139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,550.00 |
| Food and Beverage | $139.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $2,820.00 | 2019-2025 | |
| Emd Serono, INC. | $282.01 | 2020-2024 | |
| Abbvie INC. | $46.75 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $39.28 | 2021 | |
| Organon LLC | $35.57 | 2022 | |
| Hologic Sales and Service, LLC | $25.26 | 2024 | Myosure Tissue Removal Device, Omni Hysteroscope |
| Minerva Surgical, INC | $18.69 | 2025 | |
| Ferring Pharmaceuticals INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.